Health Trials

Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.

Participants needed: 300
Trial details
Phase: Phase 1, Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: PMV Pharmaceuticals, IncUpdated: Jun 26, 2026Locations: 77
Eligibility criteria

At least 18 years of age or 12 to 17 years of age after Safety Review Committee... [+7]

Anti-cancer therapy within 21 days (or 5 half-lives) of receiving the study drug [+22]

Read more
Status: Recruiting

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation.

Participants needed: 14
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: PMV Pharmaceuticals, IncUpdated: Mar 12, 2026Locations: 5
Eligibility criteria

Written informed consent [+6]

Patients with ovarian, breast, lung, or endometrial tumors who are eligible for... [+17]

Read more